Journal of the Neurological Sciences
Volume 201, Issue 1 , Pages 45-51 , 15 September 2002

Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase

Received 17 December 2001 ,Revised 19 March 2002 ,Accepted 28 May 2002.

References 

  1. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 1997;120:865–916
  2. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787–793
  3. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 1995;144:245–268
  4. Laman JD, Thompson EJ, Kappos L. Balancing the Th1/Th2 concept in multiple sclerosis. Immunol. Today. 1998;19:489–490
  5. Laman JD, van Meurs M, Schellekens MM, de Boer M, Melchers B, Massacesi L, et al.  Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J. Neuroimmunol. 1998;86:30–45
  6. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, et al.  Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J. Immunol. 2000;165:6576–6582
  7. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998;43:465–471
  8. Ochi H, Wu X-M, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al.  Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis (MS), HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis. J. Neuroimmunol. 2001;119:297–305
  9. Yamasaki K, Horiuchi I, Minohara M, Kawano Y, Ohyagi Y, Yamada T, et al.  HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain. 1999;122:1689–1696
  10. Fukazawa T, Yamasaki K, Ito H, Kikuchi S, Minohara M, Horiuchi I, et al.  Both the HLA-CPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens. 2000;55:199–205
  11. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today. 1994;15:19–26
  12. Cash E, Minty A, Ferrare O, Caput D, Fradelizi D, Rotto O. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol. 1994;153:4258–4267
  13. Young DA, Lowe LD, Booth SS, Whitters MJ, Nicholson L, Kuchroo VK, et al.  IL-4, IL-10, IL-13, and TGF-β from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 2000;164:3563–3572
  14. Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult. Scler. 2001;7:145–150
  15. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 2000;105:967–976
  16. Wiesemann E, Klatt J, Sonmez D, Blasczyk R, Heidenreich F, Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J. Neuroimmunol. 2001;119:137–144
  17. Milici AJ, Carroll LA, Stukenbrok HA, Shay AK, Gladue RP, Showell HJ. Early eosinophil infiltration into the optic nerve of mice with experimental allergic encephalomyelitis. Lab. Invest. 1998;78:1239–1244
  18. Mirsattari SM, Johnston JB, McKenna R, Del Bigio MR, Orr P, Ross RT, et al.  Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001;56:317–323
  19. Raine CS. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J. Neuroimmunol. 1997;77:135–152
  20. Nicoletti F, Marco RD, Patti F, Nicoletti A, Leonardi C, Reggio E, et al.  The anti-inflammatory cytokine interleukin-13 is not detectable in the circulation of multiple sclerosis patients and is not inducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. Autoimmunity. 2000;32:265–270
  21. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  22. Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, et al.  Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type 1 and T-cell leukemia-like cells. Ann. Neurol. 1987;21:117–122
  23. Kira J, Kanai T, Nishimura Y, Yamasaki K, Matsushita S, Kawano Y, et al.  Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann. Neurol. 1996;40:569–574
  24. Horiuchi I, Kawano Y, Yamasaki K, Minohara M, Furue M, Taniwaki T, et al.  Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J. Neurol. Sci. 2000;172:17–24
  25. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jakobson S. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J. Exp. Med. 1993;177:1567–1573
  26. Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J. Immunol. 1998;161:482–488
  27. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology. 1993;43:2679–2682
  28. Nicoletti F, Patti F, DiMarco R, Zaccone P, Nicoletti A, Meroni P, et al.  Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment. Cytokine. 1996;8:395–400
  29. Nicoletti F, Di Marco R, Patti F, Reggio E, Nicoletti A, Zaccone P, et al.  Blood levels of transforming growth factor-beta 1 (TGF-β1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-β1b). Clin. Exp. Immunol. 1998;113:96–99
  30. Chabot S, Yong VW. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS. Neurology. 2000;55:1497–1505
  31. Jung T, Schauer U, Heusser C, Neumann C, Rieger C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods. 1993;159:197–207
  32. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods. 1995;188:117–128
  33. de Vries JE. Molecular and biological characteristics of interleukin-13. Chem. Immunol. 1996;63:204–218
  34. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997;186:1677–1687
  35. Zettl UK, Mix E, Zielasek J, Stangel M, Hartung HP, Gold R. Apoptosis of myelin-reactive T cells induced by reactive oxygen and nitrogen intermediates in vitro. Cell. Immunol. 1997;178:1–8
  36. Bogdan C. The multiplex function of nitric oxide in (auto)immunity. J. Exp. Med. 1998;187:1361–1365
  37. Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 1999;163:5278–5286
  38. van der Veen RC, Dietlin TA, Dixon Gray J, Gilmore W. Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell. Immunol. 2000;199:43–49
  39. Szczepanik AM, Funes S, Petko W, Ringheim GE. IL-4, IL-10 and IL-13 modulate A beta(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J. Neuroimmunol. 2001;113:49–62
  40. Taub DD, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 1996;156:2095–2103
  41. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J. Leukoc. Biol. 1996;59:81–89
  42. van der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van DerValk P, De Groot CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathol. 1999;154:45–51
  43. Furie MB, Randolph GJ. Chemokines and tissue injury. Am. J. Pathol. 1995;146:1287–1301
  44. Johnatty RN, Taub DD, Reeder SP, Turcovski-Corrales SM, Cottam DW, Stephenson TJ, et al.  Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J. Immunol. 1997;15:2327–2333
  45. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. (Berl.). 1997;94:590–598
  46. Sironi M, Sciacca FL, Matteucci C, Conni M, Vecchi A, Bernasconi S, et al.  Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood. 1994;84:1913–1921
  47. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J. Immunol. 1995;154:799–803
  48. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 1998;84:238–249
  49. Ransohoff RM. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J. Neuroimmunol. 1999;98:57–68
  50. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 1988;130:443–454
  51. Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, et al.  Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 1995;96:2966–2974
  52. Kelly BL, Locksley RM. Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns. J. Immunol. 2000;165:2982–2986

PII: S0022-510X(02)00189-2

Journal of the Neurological Sciences
Volume 201, Issue 1 , Pages 45-51 , 15 September 2002

Article Tools

* Image Usage & Resolution